TP53 and hepatocellular carcinoma: In addition, MAGEA3 was reported to inhibit apoptosis via its action on p53-dependent BAX activation and stabilisation of surviving expression via both p53-dependent and independent mechanisms in multiple myeloma [115] and, more recently, in hepatocellular carcinoma [116].